Three Rs Approaches in the Quality Control of Inactivated Rabies Vaccines: The Report and Recommendations of ECVAM Workshop 48 1,2

Anon. (1994). ECVAM News & Views. ATLA 22, 7–11.

WHO (1998). World Survey of Rabies No. 34 for the year 1998. WHO/CDS/CSR/APH/99.6, 44 pp. Geneva, Switzerland: World Health Organization.

Dreesen D.W. (1997). A global review of rabies vaccines for human use. Vaccine 15, Suppl., S2–S6.

WHO (1994). Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines. Amendment 1992. WHO Technical Report Series No. 840, pp. 205–207. Geneva, Switzerland: World Health Organization.

OIE (2000). Rabies. In Manual of Standards for Diagnostic Tests and Vaccines, 4th edn, pp. 276–291. Paris, France: Office International des Epizooties. Web site http://www.oie.int/eng/normes/mmanual/A_summry.htm (Accessed 11.8.03).

Council of Europe (2002). The European Pharmacopoeia, 4th edn, 2416 pp. Strasbourg, France: Council of Europe.

CFR (1999). US Code of Federal Regulations, Title 9, Chapter I: Animal and Plant Health Inspection Service, Department of Agriculture, Subchapter E – Viruses, Serums, Toxins, and Analogous Products; Organisms and Vectors, Part 113.209, Rabies Vaccine, Killed Virus, pp. 601–603. Washington, DC, USA: US Government Printing Office.

Council of Europe (2002). Introduction. In The European Pharmacopoeia, 4th edn, p. iv. Strasbourg, France: Council of Europe.

Wilbur L.A. , & Aubert M.F.A. (1996). The NIH test for potency. In Laboratory Techniques in Rabies, 4th edn (ed. Meslin F-X. , Kaplan M.M. , & Koprowski H. ), pp. 360–368. Geneva, Switzerland: World Health Organization.

WHO (1987). Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines. WHO Technical Report Series No. 760, pp. 167–194. Geneva, Switzerland: World Health Organization.

Milne C. , Daas A. , Spieser J-M. , & Bruckner L. (2001). Collaborative study for the establishment of rabies vaccine (inactivated) for veterinary use. European Pharmacopoeia Biological Reference Preparation Batch No. 3. Pharmeuropa, Special Issue, BIO 2000-2, 57–64.

Aubert M.F.A. , & Blancou J. (1982). Test simplifié de contrôle d'activité des vaccins antirabiques à virus inactivés. Revue Scientifique et Technique Office International des Epizooties 1, 811–822.

Meslin F-X. , & Kaplan M.M. (1996). An overview of laboratory techniques in the diagnosis and prevention of rabies and in rabies research. In Laboratory Techniques in Rabies, 4th edn (ed. Meslin F-X. , Kaplan M.M. , & Koprowski H. ), pp. 9–27. Geneva, Switzerland: World Health Organization.

Koprowski H. (1996). The mouse inoculation test. In Laboratory Techniques in Rabies, 4th edn (ed. Meslin F-X. , Kaplan M.M. , & Koprowski H. ), pp. 80–87. Geneva, Switzerland: World Health Organization.

USDA (1999). Supplemental Assay Method for Potency Testing of Inactivated Rabies Vaccine in Mice Using the National Institutes of Health Test; MVSAM0308.01, 19 pp. Ames, IA, USA: USDA, APHIS.

Cussler K. , Morton D.B. , & Hendriksen C.F.M. (1998). Humane endpoints for the estimation of lethality rates in the potency testing of rabies vaccines. Alternativen zu Tierexperimenten 15, Suppl. 98, 40–42.

The HELP Group (2001). Humane Endpoints – Lethal Parameters: Humane Endpoints Replace Lethal Parameters in Batch Potency Tests of Rabies Vaccines, 11 pp. Bilthoven, The Netherlands: The HELP Group.

Weisser K. , & Hechler U. (1997). Animal Welfare Aspects in the Quality Control of Immunobiologicals. A Critical Evaluation of Animal Tests in Pharmacopoeial Monographs, 348 pp. Nottingham, UK: FRAME for ECVAM and the Paul-Ehrlich-Institut.

Smith J.S. , Yager P.A. , & Baer G.M. (1996). A rapid tissue culture test for determining rabies neutralising antibody. In Laboratory Techniques in Rabies, 4th edn (ed. Meslin F-X. , Kaplan M.M. , & Koprowski H. ), pp. 354–357. Geneva, Switzerland: World Health Organization.

Cliquet F. , Aubert M. , & Sagne L. (1998). Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. Journal of Immunological Methods 212, 79–87.

Arko R.J. , Wiktor T.J. , & Sikes R.K. (1973). The antibody binding test for vaccine potency. In Laboratory Techniques in Rabies (ed. Kaplan M.M. , & Koprowski H. ), pp. 292–294. Geneva, Switzerland: World Health Organization.

Barth R. , Gruschkau H. , Milcke L. , Jaeger O. , & Weinmann E. (1986). Validation of an in vitro assay for the determination of rabies antigen. Developments in Biological Standardization 64, 87–92.

Ferguson M. , Seagroatt V. , & Schild G.C. (1984). A collaborative study on the use of single radial immunodiffusion for the assay of rabies virus glycoprotein. Journal of Biological Standardization 12, 283–294.

Vogel I. , Kundi M. , & Gerstl F. (1989). A modification of the single radial immunodiffusion potency test (SRD) for rabies vaccines. Journal of Biological Standardization 17, 75–83.

Miceli G.S. , Torraba J. , Torres W. , Madero Esteves J. , & Diaz A.M. (2000). Evaluation of standard reagents for radial immunodiffusion assays. In vitro control of rabies vaccines. Revista do Instituto de Medicina Tropical Sao Paulo 42, 153–156.

Lyng J. , Bentzon M.W. , Ferguson M. , & Fitzgerald E.A. (1992). Rabies vaccine standardization: International Collaborative Study for the characterization of the fifth International Standard for rabies vaccine. Biologicals 20, 301–313.

Gupta R.K. (1996). Is the test for abnormal toxicity, general safety or innocuity necessary for vaccines? Vaccine 14, 1718.

Schwanig M. , Nagel M. , Duchow K. , & Krämer B. (1997). Elimination of abnormal toxicity test for sera and certain vaccines in the European Pharmacopoeia. Vaccine 15, 1047–1048.

Duchow K. , Schwanig M. , Krämer B. , & Nagel M. (1996). Abnormal Toxicity: a Study in the Relevance of the Requirement V.2.1.5 of the German Pharmacopoeia for Vaccines, Immunosera and Immunoglobulins. German Ministry of Research and Technology. Project No. 0310624, Final Report. Langen, Germany: Paul-Ehrlich-Institut.

WHO (2002). Abnormal toxicity test. WHO Technical Report Series No. 904, p. 10. Geneva, Switzerland: World Health Organization.

Council of Europe (2001). Vaccines for veterinary use. Pharmeuropa 13, 363–369.

Council of Europe (2002). Evaluation of safety of each batch of veterinary vaccines and immunosera. Pharmeuropa 14, 712–713.

Council of Europe (2002). Rabies vaccine (inactivated) for veterinary use (Monograph No. 0451). In The European Pharmacopoeia, 4th edn, pp. 2282–2284. Strasbourg, France: Council of Europe.

Blum S.A.E. , Braunschweiger M. , Krämer B. , Duchow K. , & Cussler K. (2001). Inactivation test for rabies vaccines ad us. vet.: a comparison of test results from in vivo and in vitro methods. Pharmeuropa, Special Issue – Proceedings – Biologicals Beyond 2000, p. 390.

Hartung T. , Aaberge I. , Berthold S. , Carlin G. , Charton E. , Coecke S. , Fennrich S. , Fischer M. , Gommer M. , Halder M. , Haslov K. , Jahnke M. , Montag-Lessing T. , Poole S. , Schechtman L. , Wendel A. , & Werner-Felmayer G. (2001). Novel pyrogen tests based on the human fever reaction. Report and recommendations of ECVAM workshop 43. ATLA 29, 99–123.

Anon. (1999). DG Research Shared Cost Action – Comparison and Validation of Novel Pyrogen Tests Based on the Human Fever Reaction; QLK3-CT-1999-00811; Web site http://www.cordis.lu (Accessed 20.9.02).

WHO (1984). WHO Expert Committee on rabies. Seventh report. WHO Technical Report Series No. 709, 104 pp. Geneva, Switzerland: World Health Organization.

Council of Europe (2002). Rabies vaccine for human use prepared in cell cultures (Monograph No. 0216). In The European Pharmacopoeia, 4th edn, pp. 2213–2214. Strasbourg, France: Council of Europe.

Gamoh K. , Senda M. , Itoh O. , Muramatsu M. , Hirayama N. , Koike R. , Endoh Y.S. , & Minamoto N. (1996). ELISA for in vitro potency test of rabies vaccines. Biologicals 24, 95–101.

Rooijakkers E. , Groen J. , Uittenbogarrd J. , van Herwijnen J. , & Osterhaus A. (1996). Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines. Developments in Biological Standardization 86, 137–145.

Perrin P. , Morgeaux S. , & Sureau P. (1990). In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralising anti-glycoprotein monoclonal antibody. Biologicals 18, 321–330.

Lafon M. , Perrin P. , Versmisse P. , & Sureau P. (1985). Use of a monoclonal antibody for quantitation of rabies vaccine glycoprotein by enzyme immunoassay. Journal of Biological Standardization 13, 295–301.

Enssle K. , Kurrle R. , Kohler R. , Muller H. , Kanzy E.J. , Hilfenhaus J. , & Seiler F.R. (1991). A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 10, 547–556.

Bunschoten H. , Gore M. , Claassen I.J. , Uytdehaag F.G. , Dietzschold B. , Wunner W.H. , & Osterhaus A.D. (1989). Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. Journal of General Virology 70, 291–298.

Lafon M. (1996). Technique for the production, screening and characterization of monoclonal antibodies. In Laboratory Techniques in Rabies, 4th edn (ed. Meslin F-X. , Kaplan M.M. , & Koprowski H. ), pp. 133–144. Geneva, Switzerland: World Health Organization.